Circulating microRNAs as novel potential diagnostic biomarkers for ovarian cancer: a systematic review and updated meta-analysis

Xinshuai Wang, Dejiu Kong, Chaokun Wang, Xuezhen Ding, Li Zhang, Mengqi Zhao, Jing Chen, Xiangyun Xu, Xiaochen Hu, Junqiang Yang, Shegan GaoJournal of Ovarian Research 2019 · DOI

Abstract

Per the meta-analysis, circulating miRNAs may be novel and non-invasive biomarkers for detecting ovarian cancer, particularly multiple miRNA panels, which have potential diagnostic value as screening tools in clinical practice.

Introduction

Ovarian cancer remains the most lethal gynecological malignancy, largely because it is often asymptomatic until it reaches an advanced stage. When caught early, the five-year survival rate is over 90%; however, for advanced cases, that number plummets to roughly 30%. Current diagnostic tools, such as the CA125 blood test and transvaginal ultrasound, often lack the necessary sensitivity and specificity for effective early-stage screening.

Researchers have turned to microRNAs (miRNAs)—small, non-coding RNA molecules that regulate gene expression—as potential biomarkers. Because miRNAs are remarkably stable in blood (serum and plasma), they are ideal candidates for non-invasive "liquid biopsy" testing. This systematic review and meta-analysis seeks to synthesize global data to determine the true diagnostic value of circulating miRNAs.

Methodology and Study Selection

The authors conducted a systematic meta-analysis following standard PRISMA guidelines. They searched major English and Chinese databases (including MEDLINE, EMBASE, and CENTRAL) for studies published through July 2017. To account for the inherent trade-off between sensitivity and specificity, they employed a bivariate random-effects model (BRM).

Flow diagram of the study selection process.

The final analysis aggregated data from 13 articles describing 33 unique studies, involving a total population of 1,081 ovarian cancer patients and 518 controls. The geographic diversity of the data spanned Asia, Europe, the United States, and Australia.

Quality Assessment

The researchers used the QUADAS-2 tool to evaluate the risk of bias and applicability of the included articles. This assessment is crucial for understanding the reliability of the pooled diagnostic metrics.

Risk of bias and applicability concerns summary (QUADAS-2).

As shown in the quality assessment, while reference standards and flow/timing generally showed low risk, there were notable concerns regarding index test bias and patient selection across several studies, which the authors addressed through meta-regression and subgroup analyses.

Key Results and Insights

The meta-analysis produced the following pooled diagnostic metrics:

  • Sensitivity: 0.89 (95% CI: 0.84–0.93)
  • Specificity: 0.64 (95% CI: 0.56–0.72)
  • Diagnostic Odds Ratio (DOR): 13.21 overall.

The Power of the Panel

The most significant finding was the performance jump when moving from single markers to miRNA panels. For multiple miRNA panels, the DOR surged to 30.06, indicating a much higher overall accuracy than single-miRNA assays (DOR 11.11). This suggests that a signature of multiple miRNAs provides a much more robust diagnostic signal than any single molecule.

Clinical Implications

  • High Rule-Out Value: With a pooled Negative Likelihood Ratio (NLR) of 0.15, these tests are particularly effective at "ruling out" ovarian cancer in patients who test negative.
  • The miR-200 Family: The study highlighted the miR-200 family (specifically miR-200a, 200b, and 200c) as particularly effective markers, reinforcing their known biological role in epithelial-to-mesenchymal transition in tumors.
  • Prospective Accuracy: Prospective studies yielded significantly higher diagnostic accuracy (DOR 21.12) compared to retrospective ones (DOR 5.88), suggesting strong potential for real-time clinical application.

Limitations and Future Work

Despite the optimistic results, significant variation between studies (high heterogeneity) remains a challenge, likely due to different specimen types (serum vs. plasma) and varying cut-off values. There is currently no "gold standard" miRNA panel, as different laboratories utilize different sets of miRNAs.

Future research must focus on large-scale, multi-center prospective trials to validate specific multi-miRNA panels and standardize quantification methods (like qPCR) to ensure these biomarkers can be reliably integrated into clinical practice.

Conclusion

Circulating miRNAs, particularly when used in multi-marker panels, represent a promising frontier for the non-invasive detection of ovarian cancer. While standardization is still required, their high sensitivity and rule-out value offer a path toward improving early diagnosis and patient outcomes.

Summary updated

Abstract

Per the meta-analysis, circulating miRNAs may be novel and non-invasive biomarkers for detecting ovarian cancer, particularly multiple miRNA panels, which have potential diagnostic value as screening tools in clinical practice.
BibTeX
@article{wang2019circulating,
  author = {Xinshuai Wang and Dejiu Kong and Chaokun Wang and Xuezhen Ding and Li Zhang and Mengqi Zhao and Jing Chen and Xiangyun Xu and Xiaochen Hu and Junqiang Yang and Shegan Gao},
  title = {{Circulating microRNAs as novel potential diagnostic biomarkers for ovarian cancer: a systematic review and updated meta-analysis}},
  journal = {Journal of Ovarian Research},
  year = {2019},
  doi = {10.1186/s13048-019-0482-8},
}
Figure